https://www.taplowgroup.comInsight
https://www.taplowgroup.comTaplow
https://www.taplowgroup.comKnowledge
  • News
  • Cases
  • Downloads
Asia Business Report - July 2021
24.07.2021

Asia Business Report - July 2021

The region is expected to recover in 2021, with an average growth of 6.8%. China's economy is expected to rebound by 7.7% in 2021, while India...
Read more
June 2021 Global Business Report
15.06.2021

June 2021 Global Business Report

The Taplow Group S.A. 20 partner firms, with 150+ consultants located in 38 office across 6 continents, combine to bring business leaders the...
Read more
May 2021 Global Business Report
17.05.2021

May 2021 Global Business Report

The Taplow Group S.A. 20 partner firms,  located in 38 office, combine to bring business leaders the latest economic and business news.

Read more
First3456789101112Last

 CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

 CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers

  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here

  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here

  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here

  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here